Shares of Novavax, Inc. (NASDAQ:NVAX – Get Free Report) have received an average rating of “Hold” from the nine ratings firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $14.00.
A number of research firms recently issued reports on NVAX. Weiss Ratings restated a “sell (d)” rating on shares of Novavax in a report on Tuesday, August 4th. Wall Street Zen raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Finally, Zacks Research cut shares of Novavax from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th.
Novavax Price Performance
Novavax (NASDAQ:NVAX – Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The company had revenue of $56.70 million for the quarter, compared to analysts’ expectations of $52.51 million. Novavax had a negative return on equity of 14.82% and a negative net margin of 59.87%. The business’s revenue for the quarter was down 76.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.62 EPS. Sell-side analysts anticipate that Novavax will post -0.48 earnings per share for the current year.
Trending Headlines about Novavax
Here are the key news stories impacting Novavax this week:
- Positive Sentiment: Broad biotech rally: Vaccine and biotechnology stocks advanced, with Novavax among the strongest performers. Positive momentum across the sector likely attracted momentum traders and helped lift NVAX on unusually heavy volume. Novavax Soars, Moderna Surges, Merck Climbs as Biotech Rallies
- Positive Sentiment: Positive vaccine-sector sentiment: Moderna’s rally following reports of a planned national cancer-vaccine effort renewed investor interest in vaccine developers generally. Although the initiative is not a Novavax project, the enthusiasm may have benefited the broader vaccine group. Moderna Stock Hits 4-Year High on Planned National Cancer Vaccine Effort
- Positive Sentiment: Plague fears eased: Reports emphasizing the World Health Organization’s assessment that epidemic risk was low reduced a short-term source of uncertainty. Earlier headlines had driven sharp volatility in NVAX despite no direct change to the company’s vaccine portfolio. Novavax Headline-Driven Volatility Around Russia Health Scare
- Neutral Sentiment: Investor attention increased: Zacks reported elevated user interest in NVAX, but provided no new fundamental catalyst. Greater visibility can support trading activity while also increasing volatility. Novavax Is Attracting Investor Attention
- Negative Sentiment: Analyst remains cautious: BofA raised its price target to $8 from $7 but maintained an Underperform rating, indicating that the firm still views the recent share price as above its fundamental expectations. BofA Adjusts Price Target on Novavax
- Negative Sentiment: Fundamental and valuation risks: Commentary warned that the rebound may have moved NVAX above fair value, while Novavax’s longer-term growth prospects remain exposed to weak sales and execution risks. Novavax Vaccine Maker Sees Momentum in 2026 but Growth Story Holds Fundamental Risks
Institutional Investors Weigh In On Novavax
Large investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC purchased a new position in Novavax in the second quarter valued at approximately $42,000. Squarepoint Ops LLC bought a new position in Novavax during the second quarter valued at $1,258,000. Allworth Financial LP grew its holdings in Novavax by 292.5% during the second quarter. Allworth Financial LP now owns 4,353 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 3,244 shares during the period. Corient Private Wealth LP bought a new position in Novavax during the second quarter valued at $155,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Novavax in the second quarter worth $739,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.
Novavax Company Profile
Novavax, Inc is a biotechnology company focused on the discovery, development and commercialization of vaccines. The company uses its recombinant protein-based vaccine platform and Matrix-M adjuvant technology to develop vaccines designed to stimulate targeted immune responses.
Novavax’s principal commercial product is its protein-based COVID-19 vaccine, marketed in various regions under the Nuvaxovid or Novavax COVID-19 Vaccine name. The vaccine has been authorized or approved in multiple markets, including the United States, Europe and other international jurisdictions, with availability and regulatory status varying by country.
Featured Stories
- Five stocks we like better than Novavax
- 3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip
- Home Depot and Lowe’s Hit 52-Week Lows—But Analysts Aren’t Giving Up
- Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally
- Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
